Business Wire

Boomi Recognized as a Leader in the 2025 Gartner ® Magic Quadrant™ for API Management

13.10.2025 15:00:00 CEST | Business Wire | Press Release

Share

Boomi™, the leader in AI-driven automation, today announced it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for API Management. This recognition reflects Boomi’s strength in both ability to execute and completeness of vision, which in Boomi’s view, reaffirms the company’s focus on powering API innovation at the core of agentic transformation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013735773/en/

Boomi Recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for API Management

“As organizations race to unlock the full value of agentic AI, APIs have never been more critical,” said Steve Lucas, Chairman and CEO at Boomi. “That’s why it’s so meaningful that Boomi is the only vendor recognized as a Leader in both the 2025 Gartner® Magic Quadrant™ for API Management and the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service. Boomi enables enterprises to manage, unify, and orchestrate APIs alongside AI agents, data, and applications, all within ONE platform. Our vision remains clear: connect everything to achieve anything.”

A Leader in Vision and Execution

Boomi is redefining API management for enterprises as a foundational capability of its broader AI-driven platform strategy. In last year's report, Boomi was positioned as a Niche Player. Boomi believes the improvement in its position highlights that its strengths lie not only in innovation but also in how the company delivers results at scale.

With a well-rounded, cloud-native platform, Boomi helps organizations tame API sprawl, scale securely, and deliver trusted data for AI. Recent enhancements build on the company’s product strategy, combining federated API management, runtime flexibility, security, and agentic AI support to accelerate innovation while maintaining enterprise-grade reliability.

Boomi’s integrated approach ensures centralized API governance across multi-gateway environments without introducing runtime latency, unlocking a new level of agility, composability, and compliance.

Global Reach and Ecosystem Expansion

Boomi’s APIM capabilities are strengthened through its global partner network and strategic alliances, particularly with ServiceNow and Amazon Web Services (AWS). These partnerships enable customers to streamline digital workflows and securely orchestrate agentic AI, accelerating their business transformation and ability to scale.

One Platform for Agentic Transformation

According to Boomi, the company's position in this year’s Gartner Magic Quadrant for API Management reflects a broader market shift toward converged integration, API, data, and AI agent orchestration. As part of the Boomi Enterprise Platform, Boomi API Management integrates seamlessly with Boomi Agentstudio, Boomi DataHub, and Boomi Data Integration, providing enterprises with a single control plane to fuel innovation and translate it into measurable business impact.

Additional Resources

  • See why Boomi was recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for API Management here
  • View the 2025 Gartner® Magic Quadrant™ for API Management here
  • Follow Boomi on X, LinkedIn, Facebook, and YouTube

Gartner Disclaimer:

Gartner® Magic Quadrant™ for API Management, Shameen Pillai, Steve Shwent, John Santoro, Nicholas Carter, October 7, 2025.

Gartner is a registered trademark and service mark, and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About Boomi

Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management in a single, comprehensive solution. Trusted by over 25,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.

© 2025 Boomi, LP. Boomi, the ‘Boomi’ logo, the ‘B’ logo, and Boomiverse are registered trademarks of Boomi, LP or its subsidiaries or affiliates in the US and other countries. All rights reserved. Other names or marks may be the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013735773/en/

Contacts

Analyst Relations Contact:
Kate Mauser
Analyst Relations
kate.mauser@boomi.com
+1.760.351.6780

Media Relations Contact:
Brandon Gubitosa
Global Corporate Communications
brandon.gubitosa@gmail.com
+1.845.642.5798

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye